Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.
about
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkThe next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy responsePolymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?Cytotoxic T-lymphocyte antigen-4 single nucleotide polymorphisms are not associated with outcomes after unrelated donor transplantation: a center for international blood and marrow transplant research analysis.Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trialA multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.CTLA-4 +49A>G polymorphism is associated with advanced non-small cell lung cancer prognosis.Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis.A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.Immunotherapy for melanoma: current status and perspectives.CTLA-4 polymorphisms and haplotype correlate with survival in ALL after allogeneic stem cell transplantation from related HLA-haplotype-mismatched donorBlockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.Germline determinants of clinical outcome of cutaneous melanoma.Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib.Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.Ipilimumab: its potential in non-small cell lung cancer.Ipilimumab: in previously treated patients with advanced melanoma.Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome.Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.The delicate balance of melanoma immunotherapy.Monitoring immune responses in the tumor microenvironment.Harnessing the immune system for the treatment of melanoma: current status and future prospects.Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.CTLA-4 and CD28 genes' polymorphisms and renal cell carcinoma susceptibility in the Polish population--a prospective study.Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitorsQ56898598Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanomaMelanoma & biomarkers of immunoresponsivenessImmune Checkpoints and Innovative Therapies in Glioblastoma
P2860
Q26785746-6203A5F5-3E0F-4203-992B-4A795AB19C8CQ28485085-06706BF6-2671-46BB-88FB-407ECE22DED9Q30384301-33EBB6A0-2605-4437-A706-EDF83E34684DQ33492805-A744C5CF-D0C5-4579-B7D0-15B9002B56F0Q33665870-106B4BF6-2E17-4F88-8CAE-66D7489B40B6Q34335379-FA4BCBA1-BBD0-4526-82AC-B58C0A305C89Q34387506-29B66DD9-87C1-433A-BB63-F0BC3F6E7935Q34395229-257A7EB8-3EA3-49D6-99D5-95A4B17A5DF0Q34631546-3C3D69FC-484D-4586-82C3-409B58FF26E5Q34651347-59772865-5476-484C-8666-46516BCF1F7AQ35079792-9A59B2E8-2C25-4DCB-84DD-E2FCBC0B54C2Q35150452-EE1E9ED7-7756-407E-9C8A-F2B4D1BDB7DFQ35617517-4DCF2DBE-B649-4599-9C0A-96E36B2DFF7DQ36086834-E38A3BFF-91E1-47FA-9009-7CE0233888CAQ36453216-D9D00B6A-7FE4-477A-AF30-2EEDA0CC6EEDQ36842615-90224664-8285-4901-ABFA-A114D186E6F7Q37014061-F63D3B3E-7E39-482B-BCC5-28DE0DE8D7BEQ37258423-23B2062B-8E96-4003-82F4-4F71F5F3C586Q37538406-F7FF1C27-2EBC-4405-BD51-FC41BBB0F8F0Q37773244-39EC36D3-C51C-425D-B90C-A935B4FB227FQ37994189-96D0983E-756A-4225-A029-54C1D27F9B9DQ38005197-11DA5BD8-395B-403E-8A9F-E836C4650076Q38127467-1D302A5A-642C-449A-ABFF-BE81F42FB2C5Q38170384-C6BEA889-ADD0-443B-AFA8-2FA6F3EF632AQ38202161-6701903F-E99B-4E6B-9F36-D3B7B31B8E22Q38217028-263AF3B0-10AF-4ADD-830E-44100E27184FQ38288116-75E61615-D398-4D4A-A96A-CB9E260AC022Q38380080-2BE09BA6-1731-4F4A-A9AE-A7124CABA110Q38806243-71D632C7-371D-4EFB-B2D4-999D1756B5B7Q38870624-CEFD74B1-F414-4BE4-8A4E-281FE79FDE2FQ40226135-1C929F53-BEE8-471C-9669-3EC908028AFCQ41321356-9EF14EE6-28C2-4100-B47E-A7D9BB400856Q42314661-011C7470-AF4C-414F-B060-67A5580E6B31Q42369277-FECA907E-490D-4B3A-8A7F-4C978AC83B27Q45839919-590DBC80-7E78-4A63-AD9D-1ED011F048B6Q56890243-F1122DD0-D071-4AA7-AC01-357B94D3837EQ56898598-0E9C4894-2265-4689-925F-6F8D0E749261Q57781473-8345F183-A724-4236-ADD8-5CC3F06DD5B9Q58234468-F43E687E-0119-4E67-99B8-1B41C79C76EBQ58573409-7615C36B-56D3-48D4-BFD9-2B428A9DFA49
P2860
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Influence of cytotoxic T lymph ...... patients with CTLA-4 blockade.
@ast
Influence of cytotoxic T lymph ...... patients with CTLA-4 blockade.
@en
type
label
Influence of cytotoxic T lymph ...... patients with CTLA-4 blockade.
@ast
Influence of cytotoxic T lymph ...... patients with CTLA-4 blockade.
@en
prefLabel
Influence of cytotoxic T lymph ...... patients with CTLA-4 blockade.
@ast
Influence of cytotoxic T lymph ...... patients with CTLA-4 blockade.
@en
P2093
P2860
P1476
Influence of cytotoxic T lymph ...... patients with CTLA-4 blockade.
@en
P2093
Eduardo Tarazona-Santos
Maureen Kiley
Renee Chen
Steven A Rosenberg
Willemijn B Breunis
P2860
P304
P356
10.1097/CJI.0B013E31817FD8F3
P577
2008-07-01T00:00:00Z